Waycross Partners LLC Buys 3,632 Shares of Becton, Dickinson and Company $BDX

Posted by Francis Steltz on Jul 20th, 2026

Waycross Partners LLC lifted its stake in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) by 3.2% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 116,966 shares of the medical instruments supplier’s stock after acquiring an additional 3,632 shares during the quarter. Becton, Dickinson and Company makes up approximately 1.8% of Waycross Partners LLC’s holdings, making the stock its 26th biggest holding. Waycross Partners LLC’s holdings in Becton, Dickinson and Company were worth $18,391,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Imprint Wealth LLC bought a new position in Becton, Dickinson and Company in the third quarter worth approximately $25,000. Steph & Co. raised its position in Becton, Dickinson and Company by 95.6% during the 4th quarter. Steph & Co. now owns 133 shares of the medical instruments supplier’s stock valued at $26,000 after purchasing an additional 65 shares in the last quarter. SHP Wealth Management purchased a new stake in shares of Becton, Dickinson and Company in the 4th quarter worth $26,000. Main Street Group LTD purchased a new stake in shares of Becton, Dickinson and Company in the 1st quarter worth $29,000. Finally, Prosperity Bancshares Inc bought a new position in shares of Becton, Dickinson and Company during the 4th quarter worth $29,000. Institutional investors own 86.97% of the company’s stock.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, CEO Thomas E. Polen, Jr. sold 2,764 shares of Becton, Dickinson and Company stock in a transaction on Monday, June 1st. The shares were sold at an average price of $146.35, for a total value of $404,511.40. Following the transaction, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at approximately $16,122,355.05. The trade was a 2.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of the company’s stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total value of $160,226.00. Following the transaction, the executive vice president directly owned 13,172 shares in the company, valued at approximately $1,918,633.52. The trade was a 7.71% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 5,188 shares of company stock valued at $765,120. 0.40% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Trading Down 0.0%

BDX opened at $158.14 on Monday. The company has a current ratio of 0.94, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The firm has a market cap of $43.57 billion, a price-to-earnings ratio of 40.04, a PEG ratio of 11.19 and a beta of 0.21. Becton, Dickinson and Company has a 12 month low of $127.59 and a 12 month high of $187.35. The stock has a fifty day moving average price of $148.99 and a 200-day moving average price of $166.18.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share for the quarter, beating analysts’ consensus estimates of $2.77 by $0.13. The company had revenue of $4.71 billion for the quarter, compared to the consensus estimate of $4.67 billion. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The firm’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same quarter last year, the company earned $3.35 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. As a group, equities research analysts anticipate that Becton, Dickinson and Company will post 12.62 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 30th. Stockholders of record on Tuesday, June 9th were given a $1.05 dividend. The ex-dividend date of this dividend was Tuesday, June 9th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.7%. Becton, Dickinson and Company’s payout ratio is presently 106.33%.

Analysts Set New Price Targets

Several analysts recently weighed in on BDX shares. Bank of America decreased their price objective on Becton, Dickinson and Company from $177.00 to $170.00 in a report on Friday, June 12th. Evercore set a $180.00 target price on shares of Becton, Dickinson and Company in a report on Monday, July 6th. Weiss Ratings downgraded shares of Becton, Dickinson and Company from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, May 11th. Stifel Nicolaus reduced their price target on shares of Becton, Dickinson and Company from $215.00 to $175.00 in a report on Thursday, May 7th. Finally, The Goldman Sachs Group lowered their price target on shares of Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating for the company in a research report on Wednesday, May 27th. Seven equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Becton, Dickinson and Company presently has a consensus rating of “Hold” and a consensus target price of $180.29.

Get Our Latest Analysis on BDX

Becton, Dickinson and Company Profile

(Free Report)

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.